Developer docs
API playgroundTry for free, no card

Search company profiles

MediBeacon

Full company profile

uuid0002asw

Namestring
MediBeacon
Legal namestring
MediBeacon Inc.
Websiteurl
medibeacon.com
Company typeenum
Private
Founded yearint
2012
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSt Louis, United States
HQ citystring
St Louis
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
fluorescent tracer agents, transdermal GFR measurement, kidney function diagnostics, optical diagnostic devices, preclinical imaging systems
Industry3 codes
PRIMARYHLAHAKAJ
Renal Diagnostics & Monitoring (eGFR/Creatinine POC, Urine Analyzers, BP/Fluid Status)
SECONDARYHLAHAOAE
Urinalysis & Kidney Function POCT (Dipstick, Microalbumin, Creatinine)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLAHAAAG
Urinalysis & Routine Screening Diagnostics
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
NAICS code2 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Surgical & Medical Instruments & Apparatus3841
Product category
Optical Diagnostics / Kidney Function Assessment
Social media profiles3 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1TGFR System Hardware Sales
TypeHardware Sales
Description

Sale of TGFR monitors and reusable sensors to healthcare facilities, academic medical centers, and hospitals for point-of-care kidney function assessment.

medibeacon.com
2Lumitrace (Relmapirazin) Tracer Agent
TypeHardware Sales
Description

Single-use injectable fluorescent tracer agent (Lumitrace) used with the TGFR system. The tracer agent is a consumable that must be administered during each GFR assessment session.

medibeacon.com
3Preclinical Products
TypeHardware Sales
Description

Sale of Preclinical MX devices and related consumables (fluorescent tracer agents, measurement codes) for preclinical animal research. The product enables longitudinal GFR measurements in conscious, freely-moving animals.

medibeacon.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure
Pricing details1 tier
1Medical device pricing for healthcare institutions
ModelOtherBilling cadenceMulti-year contract
Notes

Quote-based pricing for TGFR monitors, reusable sensors, and Lumitrace tracer agents. Pricing negotiated based on institution volume and requirements.

medibeacon.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1TGFR
Description

Transdermal Glomerular Filtration Rate system for kidney function assessment

medibeacon.com
+2 more records
Core offering1 text field

MediBeacon develops and commercializes fluorescent tracer agent-based transdermal diagnostic systems, with its core product being the TGFR (Transdermal Glomerular Filtration Rate) System that includes Lumitrace (relmapirazin) injection, a TGFR Monitor, a Reusable Sensor, and a Disposable Ring for non-invasive point-of-care kidney function assessment. The company also offers the Preclinical MX device and related software for longitudinal GFR measurement in conscious, freely-moving laboratory animals, alongside a research pipeline extending the fluorescent tracer platform into gastrointestinal permeability, ocular angiography, and surgical visualization applications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Non-invasive GFR assessment without blood draws, urine sampling, or lab analysis
+3 more records
Product overview1 text field

MediBeacon is a medical technology company offering a portfolio of fluorescent tracer agent-based transdermal detection systems. The core product is the TGFR (Transdermal Glomerular Filtration Rate) System, which includes Lumitrace (relmapirazin) injection as the fluorescent tracer agent, the TGFR Monitor for displaying data, the TGFR Reusable Sensor for transdermal detection, and the TGFR Disposable Ring as a single-use component. The system received FDA approval in December 2025, CE Mark in March 2026, and China NMPA approval in October 2025. For preclinical research, the company offers the Preclinical MX device along with Lab 3 and Studio 3 software. Applications span nephrology (kidney function assessment), gastroenterology (GI permeability), ophthalmology (ocular angiography), and surgery (ureter visualization).

Product and service6 records
1MediBeacon TGFR System
CategoryOptical Diagnostics / Kidney Function Assessment
Description

Transdermal Glomerular Filtration Rate measurement system that non-invasively assesses kidney function by measuring fluorescent tracer agent clearance through transdermal detection. The system includes Lumitrace injection, a monitor, and reusable sensor, and is FDA-approved for assessing GFR in adult patients with impaired or normal renal function.

2Lumitrace (relmapirazin) Injection
CategoryDiagnostic Consumables / Fluorescent Tracer Agents
Description

Exogenous pyrazine-based fluorescent tracer agent administered as an IV bolus injection. Engineered to be inert, highly fluorescent, and have clearance properties of a GFR tracer agent, with negligible protein binding, negligible metabolism, and physiologic pH formulation. Detected transdermally to measure kidney function.

3MediBeacon TGFR Monitor
CategoryMedical Device Hardware / Monitor
Description

Medical device that displays fluorescence data collected during monitoring sessions. The Average Session GFR is displayed at the end of a full session, which may last 6 to 24 hours depending on renal function. CE Mark certified under EU MDR as a Class IIa device.

4MediBeacon TGFR Reusable Sensor
CategoryMedical Device Hardware / Sensor
Description

Non-invasive sensor engineered to measure the intensity of Lumitrace injection 2.5 times per second continuously throughout the monitoring session. Placed on the patient's skin to measure fluorescence transdermally, automatically adjusting for different skin tones and compensating for tissue properties. Validated across diverse Fitzpatrick skin types and CE Mark certified under EU MDR.

5MediBeacon TGFR Disposable Ring
CategoryDiagnostic Consumables / Single-use Accessories
Description

Single-use component intended to be assembled with the TGFR Reusable Sensor and attached to the patient's skin during a TGFR session. Part of the TGFR System cleared under PMA No. P230019.

6MediBeacon Preclinical MX
CategoryPreclinical Research Instruments
Description

Transdermal GFR monitoring system for preclinical (animal) nephrology research. Enables longitudinal GFR measurements in conscious, freely-moving mice, rats, and larger animals. Used by leading medical schools, research institutes, and pharmaceutical companies worldwide.

Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1Huadong Medicine Co., Ltd.
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2019-01-01
Description

Exclusive commercialization partnership for Greater China. Huadong Medicine invested $30 million in 2019 and provided an additional $10 million in amended agreements in 2022. Huadong is a leading Chinese pharmaceutical company listed on Shenzhen Stock Exchange with integrated R&D, manufacturing, distribution, and sales capabilities across oncology, immunology, nephrology, diabetes, GI, and operating rooms.

medibeacon.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2016-01-01
Description

Collaboration with Washington University School of Medicine in St. Louis for research on childhood malnutrition and gut permeability. Funded by Bill & Melinda Gates Foundation Grand Challenges Explorations Phase II grant of $1.1 million to Washington University. Led by Dr. Phillip I. Tarr, Director of Pediatric Gastroenterology.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research collaboration with Mayo Clinic for gut permeability studies using MediBeacon fluorescent tracer agent-based systems.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research partnership with investigators at Imperial College London for gastrointestinal permeability research.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Dr. Stuart L. Goldstein serves as MediBeacon Director of Clinical Development. He is Professor of Pediatrics and Director of the Center for Acute Care Nephrology at Cincinnati Children's Hospital.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Siemens offers laboratory creatinine assays and POC blood gas analyzers with creatinine modules used for GFR estimation. As a major clinical diagnostics incumbent, Siemens competes across the workflow where MediBeacon's transdermal system could displace conventional creatinine-based GFR assessment.

TypeDirect peer
Description

Nova Biomedical manufactures point-of-care creatinine analyzers (StatSensor Creatinine) that provide rapid GFR estimates at the bedside. Direct comparability to MediBeacon in the POC kidney function assessment category, though Nova's approach uses blood-based creatinine rather than fluorescent tracer clearance.

TypeBroad incumbent
Description

Roche offers the cobas platform for laboratory creatinine testing and eGFR calculation, alongside a broader menu of clinical chemistry assays. As the world's largest diagnostics company, Roche represents the established infrastructure that MediBeacon's transdermal system would need to displace or complement.

TypeEmerging player
Description

Quanterix offers ultra-sensitive biomarker detection platforms (Simoa) used in research and clinical applications including nephrology. Comparable as an emerging diagnostics platform company developing novel measurement technologies for kidney disease and adjacent therapeutic areas.

TypeBroad incumbent
Description

Fresenius is the global leader in dialysis services and renal care products, serving the same CKD and ESRD patient population MediBeacon targets. While Fresenius's core business is dialysis rather than diagnostics, it represents the dominant commercial force in renal care that MediBeacon must position against in GFR assessment.

TypeEmerging player
Description

Metabolon applies metabolomics profiling to identify biomarkers for chronic kidney disease progression and other conditions. Comparable as an emerging biomarker discovery and diagnostic company targeting the same renal patient population, though using mass spectrometry rather than fluorescent tracer approaches.

TypeBroad incumbent
Description

bioMérieux acquired Astute Medical, whose NephroCheck test measures urinary biomarkers (TIMP-2, IGFBP7) for acute kidney injury risk assessment. Directly comparable to MediBeacon in the kidney function diagnostic category, though focused on AKI prediction rather than continuous GFR measurement.

TypeBroad incumbent
Description

QuidelOrtho (formed by merger of Quidel and Ortho Clinical Diagnostics) provides clinical laboratory diagnostics including creatinine assays used for GFR estimation. Comparable as an incumbent diagnostics provider in the kidney function testing workflow.

TypeEmerging player
Description

Spectral Medical develops diagnostics for acute kidney injury and sepsis, including the PMX endotoxin removal column. Comparable as an emerging company targeting renal diagnostics with novel technology approaches, though Spectral focuses on therapeutic intervention rather than continuous monitoring.

10Abbott Diagnostics
TypeBroad incumbent
Description

Abbott offers the i-STAT system for POC creatinine measurement, a foundational alternative to transdermal GFR in many hospital settings. As a major diagnostics incumbent, Abbott competes across the broader renal assessment workflow and benefits from established hospital relationships and reimbursement infrastructure.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MediBeacon

Optical Diagnostics / Kidney Function Assessmentmedibeacon.com

MediBeacon firmographics

Firmographics
Name
MediBeacon
Legal name
MediBeacon Inc.
Website
https://medibeacon.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

MediBeacon industry classification

Industry
Product category
Optical Diagnostics / Kidney Function Assessment
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAKAJ
Renal Diagnostics & Monitoring (eGFR/Creatinine POC, Urine Analyzers, BP/Fluid Status)
SECONDARYHLAHAOAE
Urinalysis & Kidney Function POCT (Dipstick, Microalbumin, Creatinine)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLAHAAAG
Urinalysis & Routine Screening Diagnostics
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics

Keywords

  • Fluorescent tracer agents
  • Transdermal GFR measurement
  • Kidney function diagnostics
  • Optical diagnostic devices
  • Preclinical imaging systems

Where MediBeacon is headquartered

Location

Headquarters

HQ city
St Louis
HQ country
United States
HQ region
North America

Offices3 records

Markets served

MediBeacon business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. TGFR System Hardware Sales: Sale of TGFR monitors and reusable sensors to healthcare facilities, academic medical centers, and hospitals for point-of-care kidney function assessment.
  2. Lumitrace (Relmapirazin) Tracer Agent: Single-use injectable fluorescent tracer agent (Lumitrace) used with the TGFR system. The tracer agent is a consumable that must be administered during each GFR assessment session.
  3. Preclinical Products: Sale of Preclinical MX devices and related consumables (fluorescent tracer agents, measurement codes) for preclinical animal research. The product enables longitudinal GFR measurements in conscious, freely-moving animals.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractMedical device pricing for healthcare institutions

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

MediBeacon product offering

Product offering

Core offering

MediBeacon develops and commercializes fluorescent tracer agent-based transdermal diagnostic systems, with its core product being the TGFR (Transdermal Glomerular Filtration Rate) System that includes Lumitrace (relmapirazin) injection, a TGFR Monitor, a Reusable Sensor, and a Disposable Ring for non-invasive point-of-care kidney function assessment. The company also offers the Preclinical MX device and related software for longitudinal GFR measurement in conscious, freely-moving laboratory animals, alongside a research pipeline extending the fluorescent tracer platform into gastrointestinal permeability, ocular angiography, and surgical visualization applications.

Product overview

MediBeacon is a medical technology company offering a portfolio of fluorescent tracer agent-based transdermal detection systems. The core product is the TGFR (Transdermal Glomerular Filtration Rate) System, which includes Lumitrace (relmapirazin) injection as the fluorescent tracer agent, the TGFR Monitor for displaying data, the TGFR Reusable Sensor for transdermal detection, and the TGFR Disposable Ring as a single-use component. The system received FDA approval in December 2025, CE Mark in March 2026, and China NMPA approval in October 2025. For preclinical research, the company offers the Preclinical MX device along with Lab 3 and Studio 3 software. Applications span nephrology (kidney function assessment), gastroenterology (GI permeability), ophthalmology (ocular angiography), and surgery (ureter visualization).

Differentiator

Problem solved

Functional benefit

Brands

  • TGFR: Transdermal Glomerular Filtration Rate system for kidney function assessment
  • Lumitrace
  • 敏狄康 (Mindikang)

Products and services

  • MediBeacon TGFR System Transdermal Glomerular Filtration Rate measurement system that non-invasively assesses kidney function by measuring fluorescent tracer agent clearance through transdermal detection. The system includes Lumitrace injection, a monitor, and reusable sensor, and is FDA-approved for assessing GFR in adult patients with impaired or normal renal function.
  • Lumitrace (relmapirazin) Injection Exogenous pyrazine-based fluorescent tracer agent administered as an IV bolus injection. Engineered to be inert, highly fluorescent, and have clearance properties of a GFR tracer agent, with negligible protein binding, negligible metabolism, and physiologic pH formulation. Detected transdermally to measure kidney function.
  • MediBeacon TGFR Monitor Medical device that displays fluorescence data collected during monitoring sessions. The Average Session GFR is displayed at the end of a full session, which may last 6 to 24 hours depending on renal function. CE Mark certified under EU MDR as a Class IIa device.
  • MediBeacon TGFR Reusable Sensor Non-invasive sensor engineered to measure the intensity of Lumitrace injection 2.5 times per second continuously throughout the monitoring session. Placed on the patient's skin to measure fluorescence transdermally, automatically adjusting for different skin tones and compensating for tissue properties. Validated across diverse Fitzpatrick skin types and CE Mark certified under EU MDR.
  • MediBeacon TGFR Disposable Ring Single-use component intended to be assembled with the TGFR Reusable Sensor and attached to the patient's skin during a TGFR session. Part of the TGFR System cleared under PMA No. P230019.
  • MediBeacon Preclinical MX Transdermal GFR monitoring system for preclinical (animal) nephrology research. Enables longitudinal GFR measurements in conscious, freely-moving mice, rats, and larger animals. Used by leading medical schools, research institutes, and pharmaceutical companies worldwide.

Quantifiable outcome

  • Non-invasive GFR assessment without blood draws, urine sampling, or lab analysis
  • +3 more outcomes

Companies that use MediBeacon

Customer profile

Named customers3 records

Segments5 records

Ideal customer profiles4 records

MediBeacon technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature6 records

MediBeacon partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • Huadong Medicine Co., Ltd.coreChannel Partner/ Reseller/ Distributor · 1 January 2019Exclusive commercialization partnership for Greater China. Huadong Medicine invested $30 million in 2019 and provided an additional $10 million in amended agreements in 2022. Huadong is a leading Chinese pharmaceutical company listed on Shenzhen Stock Exchange with integrated R&D, manufacturing, distribution, and sales capabilities across oncology, immunology, nephrology, diabetes, GI, and operating rooms.
  • Washington University School of MedicineminorStrategic or Co-development Partner · 1 January 2016Collaboration with Washington University School of Medicine in St. Louis for research on childhood malnutrition and gut permeability. Funded by Bill & Melinda Gates Foundation Grand Challenges Explorations Phase II grant of $1.1 million to Washington University. Led by Dr. Phillip I. Tarr, Director of Pediatric Gastroenterology.
  • Mayo ClinicminorStrategic or Co-development PartnerResearch collaboration with Mayo Clinic for gut permeability studies using MediBeacon fluorescent tracer agent-based systems.
  • Imperial College LondonminorStrategic or Co-development PartnerResearch partnership with investigators at Imperial College London for gastrointestinal permeability research.
  • Cincinnati Children's Hospital Medical CenterminorStrategic or Co-development PartnerDr. Stuart L. Goldstein serves as MediBeacon Director of Clinical Development. He is Professor of Pediatrics and Director of the Center for Acute Care Nephrology at Cincinnati Children's Hospital.

Scale indicators14 records

Recent moves6 records

Expansion highlights7 records

MediBeacon competitors and assessment

Company assessment

Broad incumbents

  • Siemens Healthineers: Siemens offers laboratory creatinine assays and POC blood gas analyzers with creatinine modules used for GFR estimation. As a major clinical diagnostics incumbent, Siemens competes across the workflow where MediBeacon's transdermal system could displace conventional creatinine-based GFR assessment.
  • Roche Diagnostics: Roche offers the cobas platform for laboratory creatinine testing and eGFR calculation, alongside a broader menu of clinical chemistry assays. As the world's largest diagnostics company, Roche represents the established infrastructure that MediBeacon's transdermal system would need to displace or complement.
  • Fresenius Medical Care: Fresenius is the global leader in dialysis services and renal care products, serving the same CKD and ESRD patient population MediBeacon targets. While Fresenius's core business is dialysis rather than diagnostics, it represents the dominant commercial force in renal care that MediBeacon must position against in GFR assessment.
  • bioMérieux (including Astute Medical): bioMérieux acquired Astute Medical, whose NephroCheck test measures urinary biomarkers (TIMP-2, IGFBP7) for acute kidney injury risk assessment. Directly comparable to MediBeacon in the kidney function diagnostic category, though focused on AKI prediction rather than continuous GFR measurement.
  • QuidelOrtho: QuidelOrtho (formed by merger of Quidel and Ortho Clinical Diagnostics) provides clinical laboratory diagnostics including creatinine assays used for GFR estimation. Comparable as an incumbent diagnostics provider in the kidney function testing workflow.
  • Abbott Diagnostics: Abbott offers the i-STAT system for POC creatinine measurement, a foundational alternative to transdermal GFR in many hospital settings. As a major diagnostics incumbent, Abbott competes across the broader renal assessment workflow and benefits from established hospital relationships and reimbursement infrastructure.

Direct peers

  • Nova Biomedical: Nova Biomedical manufactures point-of-care creatinine analyzers (StatSensor Creatinine) that provide rapid GFR estimates at the bedside. Direct comparability to MediBeacon in the POC kidney function assessment category, though Nova's approach uses blood-based creatinine rather than fluorescent tracer clearance.

Emerging players

  • Quanterix: Quanterix offers ultra-sensitive biomarker detection platforms (Simoa) used in research and clinical applications including nephrology. Comparable as an emerging diagnostics platform company developing novel measurement technologies for kidney disease and adjacent therapeutic areas.
  • Metabolon: Metabolon applies metabolomics profiling to identify biomarkers for chronic kidney disease progression and other conditions. Comparable as an emerging biomarker discovery and diagnostic company targeting the same renal patient population, though using mass spectrometry rather than fluorescent tracer approaches.
  • Spectral Medical: Spectral Medical develops diagnostics for acute kidney injury and sepsis, including the PMX endotoxin removal column. Comparable as an emerging company targeting renal diagnostics with novel technology approaches, though Spectral focuses on therapeutic intervention rather than continuous monitoring.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

MediBeacon social profiles

Digital presence

MediBeacon compliance and trust

Trust signal

Compliance3 records

MediBeacon financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MediBeacon leadership team

Management profile

Number of profiles

Profiles7 records

MediBeacon subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

MediBeacon funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MediBeacon M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MediBeacon

What does MediBeacon do?

MediBeacon develops and commercializes fluorescent tracer agent-based transdermal diagnostic systems, with its core product being the TGFR (Transdermal Glomerular Filtration Rate) System that includes Lumitrace (relmapirazin) injection, a TGFR Monitor, a Reusable Sensor, and a Disposable Ring for non-invasive point-of-care kidney function assessment. The company also offers the Preclinical MX device and related software for longitudinal GFR measurement in conscious, freely-moving laboratory animals, alongside a research pipeline extending the fluorescent tracer platform into gastrointestinal permeability, ocular angiography, and surgical visualization applications.

Is MediBeacon a public or private company?

MediBeacon is a private company. It is classified as corporate owned and is currently operating.

When was MediBeacon founded?

MediBeacon was founded in 2012. It employs 11 to 50 people.

Where is MediBeacon based?

MediBeacon is headquartered in St Louis, United States, in the North America region.

How does MediBeacon make money?

Three revenue lines are on record. TGFR System Hardware Sales are the primary driver. The others are lumitrace (Relmapirazin) Tracer Agent and preclinical Products.

Who are MediBeacon's main competitors?

Broad incumbents on record are Siemens Healthineers, Roche Diagnostics, Fresenius Medical Care, bioMérieux (including Astute Medical), QuidelOrtho and Abbott Diagnostics. Nova Biomedical is listed as a direct peer. Emerging players are Quanterix, Metabolon and Spectral Medical.

Does MediBeacon have an API?

No public API is recorded for MediBeacon.

What industry is MediBeacon in?

MediBeacon's product category is Optical Diagnostics / Kidney Function Assessment. Its primary akta.pro industry code is HLAHAKAJ, Renal Diagnostics & Monitoring (eGFR/Creatinine POC, Urine Analyzers, BP/Fluid Status), with a secondary code of HLAHAOAE, Urinalysis & Kidney Function POCT (Dipstick, Microalbumin, Creatinine). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireMediBeacon passes three audits in six weeks with zero major findings using Greenlight GuruMediBeacon passed three audits in six weeks with zero major findings using Greenlight Guru's eQMS. The audits covered ISO 13485, MDSAP, and MDR, and the company recently launched a new product in the US and China.GlobeNewswireMediBeacon Transdermal GFR System Nominated for 2026 PrixMediBeacon Inc. announced that its TGFR System, a transdermal kidney function assessment device, was nominated for the 2026 Prix Galien USA Best Medical Technology. The system uses a fluorescent tracer injection and a reusable sensor to measure glomerular filtration rate. Winners will be announced at the Prix Galien USA Awards Ceremony on October 29, 2026.Stock TitanINNOVATE: MediBeacon System Nominated for 2026 Prix GalienINNOVATE Corp. announced that its equity method investment, MediBeacon Inc., has been nominated for the 2026 Prix Galien USA Best Medical Technology award for its MediBeacon TGFR System. The nomination recognizes the system as a first-in-kind transdermal device for point-of-care kidney function assessment, with winners to be announced in October 2026. This recognition follows peer-reviewed validation of the technology's accuracy published earlier this year.YahooMediBeacon Transdermal GFR System Nominated for 2026 Prix Galien USA Best Medical TechnologyMediBeacon Inc. announced that its TGFR System was nominated for the 2026 Prix Galien USA Best Medical Technology. The system measures kidney function via transdermal detection of a fluorescent tracer. Winners will be announced at the ceremony on October 29, 2026.Stock TitanINNOVATE Q2 Earnings: $421.6M Revenue, $10.4M Net IncomeINNOVATE Corp. reported Q2 2026 revenue of $421.6 million, up 74.2% year-over-year, with net income of $10.4 million compared to a net loss of $22.0 million in the prior year quarter, driven primarily by its Infrastructure segment. DBM Global delivered record results with revenue of $414.0 million, up 77.6%, and adjusted backlog reaching a record $2.7 billion, while Broadcasting completed a $105 million refinancing and entered a merger agreement to sell a 75% stake to CONX Corp., with INNOVATE retaining 25% through HC2 Holdco. The company also continued portfolio restructuring, pursuing asset dispositions including a sales process for DBMG and advancing Life Sciences commercialization at MediBeacon and R2 Technologies.EIN PresswireDisposable Medical Sensors Market Size to Hit US$32.9 Bn by 2033 | Persistence Market ResearchThe global disposable medical sensors market is projected to grow from US$13.9 billion in 2026 to US$32.9 billion by 2033, a CAGR of 13.1%. North America leads with a 39% share, while biosensors hold 47% of the product segment. Growth is driven by chronic disease prevalence and remote monitoring, with environmental and supply chain challenges noted.Seeking AlphaINNOVATE Stock Q4: MediBeacon Sale Could Be Only Saving Grace, Downgrade To Sell (VATE)INNOVATE Corp. (VATE) has been downgraded from Hold to Sell due to significant financial distress including $687.2 million in debt, missed covenants, and substantial doubt about its going concern status as debt maturities loom. Despite MediBeacon receiving FDA, China, and EU approvals with a $1.8 billion DBM backlog and 27.6% Q4 Life Sciences revenue growth, early-stage commercialization and potential forced asset sales limit the company's ability to capture upside value. Management's limited visibility into future operations heightens downside risk for investors.Medical Device NetworkMediBeacon secures CE Mark certification for TGFR monitor and sensorMediBeacon has received CE Mark certification under the EU Medical Device Regulation for its transdermal glomerular filtration rate (TGFR) monitor and reusable sensor, confirming compliance with EU MDR 2017/745 safety, quality, and performance standards. The two Class IIa devices, alongside the Lumitrace injection and TGFR disposable ring, form a system that assesses kidney function by measuring the clearance of a fluorescent agent called relmapirazin. The certification enables potential use of the transdermal technology in clinical trials including European sites, with the system already approved by the FDA and China's NMPA.Stock TitanINNOVATE's MediBeacon wins EU CE Mark for GFR monitorINNOVATE Corp. announced that its equity method investment MediBeacon Inc. received EU CE Mark certification under the European Medical Device Regulation for its TGFR Monitor and TGFR Reusable Sensor, confirming the devices meet EU safety, quality, and performance standards. The TGFR System enables transdermal assessment of kidney function by measuring the clearance rate of a fluorescent agent, and the CE Mark allows for potential use of the technology in clinical trials with European sites. Lumitrace injection, a key component of the system, is already approved in the U.S. and China, with EU regulatory submission pending.GlobeNewswireMediBeacon® Transdermal GFR Monitor and Reusable Sensor Receive CE Mark Under European Medical Device RegulationMediBeacon Inc. received EU CE Mark certification under the Medical Device Regulation for its TGFR Monitor and Reusable Sensor. The two Class IIa devices, plus the Lumitrace injection and disposable ring, form the TGFR System for transdermal kidney function assessment. Submission of the injection to EU authorities is pending.